Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 280 for:    Panama

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age (VIPV-07)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03025750
Recruitment Status : Completed
First Posted : January 19, 2017
Last Update Posted : November 14, 2018
Sponsor:
Collaborators:
Bill and Melinda Gates Foundation
Larix A/S
Vaxtrials S.A.
AJ Vaccines
Information provided by (Responsible Party):
Statens Serum Institut

Brief Summary:
The trial is a phase III, non-inferiority, observer-blind, randomised, active controlled, multicentre clinical trial with 2 parallel groups: IPV-Al SSI (investigational vaccine) and IPV SSI (comparator vaccine). The vaccines will be administered at 2, 4 and 6 months of age.

Condition or disease Intervention/treatment Phase
Poliomyelitis Biological: IPV-Al SSI Biological: IPV SSI Phase 3

Detailed Description:

In addition to the trial vaccines (IPV-Al SSI or IPV SSI), the trial subjects will receive concomitant childhood vaccinations during the trial period. The trial vaccine (IPV-Al SSI or IPV SSI) is administered in the RIGHT thigh, whereas the other injectable childhood vaccines are administered in the opposite (LEFT) thigh.

At Visit 1 (inclusion, screening, blood sample, randomisation and 1st vaccination), written informed consent is obtained and the subject's eligibility is assessed according to the pre-specified in-/exclusion criteria. Information on medical history, demographics and concomitant medication are collected and a physical examination is performed and vital signs are measured. A prevaccination blood sample is taken for polio antibody determinations and the subject is randomly allocated into one of the two vaccination groups and vaccinated. A subset of 200 subjects are randomly chosen to have an extra blood sample taken at Visit 3. The subject is observed for immediate AEs 30 minutes after all vaccinations. An eDiary, thermometer and ruler are handed out to the parents for measurements of temperature and recording of injection site reactions and solicited systemic AEs. These activities are performed daily, starting on the day of the vaccination and the following 2 days and until resolved, and for recording of any other AEs as instructed by the trial staff. A contact to the parents via telephone will be made after the vaccination visit to remind the parents to fill in the eDiary and to check if they have any questions regarding how use the eDiary.

At Visit 2 (2nd vaccination), 2 months after Visit 1, the eDiary is collected and AEs and concomitant medications are recorded. Contraindications are reviewed, the 2nd vaccination is administered, immediate reactions are observed and the eDiary is returned to the partents for recordings of AEs and concomitant medications. A contact to the parents via telephone will be made after the vaccination visit to remind the parents to fill in the eDiary and to check if they have any questions regarding how use the eDiary.

At Visit 3 (3rd vaccination), 2 months after Visit 2, the eDiary is collected and AEs and concomitant medication are recorded. A blood sample from a subset of the subjects is taken for polio antibody determinations. Contraindications are reviewed, the 3rd vaccination is given, immediate reactions are observed and the eDiary is returned to the parents. A contact to the parents via telephone will be made after the vaccination visit to remind the parents to fill in the eDiary and to check if they have any questions regarding how use the eDiary.

At Visit 4 (blood sample and trial completion), 1 month after Visit 3, the eDiary is collected and AEs and concomitant medications are recorded and a blood sample for polio antibody determination is taken.

A safety follow-up telephone call will be conducted at 12 months of age.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al SSI, in Comparison to Non-adjuvanted Full Dose IPV SSI, in Infants Vaccinated at 2, 4 and 6 Months of Age
Actual Study Start Date : January 19, 2017
Actual Primary Completion Date : November 14, 2017
Actual Study Completion Date : November 14, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: IPV-Al SSI
IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
Biological: IPV-Al SSI
Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age

Active Comparator: IPV SSI
IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
Biological: IPV SSI
Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
Other Name: IPV Vaccine SSI




Primary Outcome Measures :
  1. Seroconversion for poliovirus type 1, 2 and 3 for IPV-Al compared to IPV SSI in infants [ Time Frame: Change from baseline to one month after 3rd vaccination ]

Secondary Outcome Measures :
  1. Adverse events following vaccinations (key secondary) [ Time Frame: After primary injections at 2, 4 and 6 months of age ]
  2. Subjects with seroprotection against poliovirus types 1, 2 and 3 [ Time Frame: One months after 3rd vaccination ]
  3. Subjects with poliovirus types 1, 2 and 3 post-vaccination titres >= 4-fold above estimated titre of maternal antibody [ Time Frame: One months after 3rd vaccination ]
  4. Geometric mean titres (GMTs) and median titers for poliovirus types 1, 2 and 3 [ Time Frame: One months after 3rd vaccination ]
  5. Reverse cumulative titre distribution curves for poliovirus types 1, 2 and 3 [ Time Frame: From baseline and one months after 3rd vaccination ]

Other Outcome Measures:
  1. Subject with seroconversion against poliovirus types 1, 2 and 3 [ Time Frame: Two months after 2nd vaccination ]
  2. Subjects with seroprotection against poliovirus types 1, 2 and 3 [ Time Frame: Two months after 2nd vaccination ]
  3. Subjects with poliovirus types 1, 2 and 3 post-vaccination titres ≥ 4-fold above estimated titre of maternal antibody [ Time Frame: Two months after 2nd vaccination ]
  4. Geometric mean titres (GMTs) and median titers for poliovirus types 1, 2 and 3 [ Time Frame: Two months after 2nd vaccination ]
  5. Reverse cumulative titre distribution curves for poliovirus types 1, 2 and 3 [ Time Frame: From baseline and two months after 2nd vaccination ]
  6. Sensitivity analysis: subjects with ≥ 4-fold increases in poliovirus types 1, 2 and 3 titres [ Time Frame: From baseline and one months after 3rd vaccination ]
  7. Sensitivity analysis: sub-groups of subjects with seroprotection (titre ≥ 8) and without seroprotection (titre < 8) at baseline [ Time Frame: One months after 3rd vaccination ]
    • Subjects with seroconversion against poliovirus types 1, 2 and 3
    • Subjects with seroprotection (titre ≥ 8) against poliovirus types 1, 2 and 3
    • Subjects with poliovirus types 1, 2 and 3 post-vaccination titres ≥ 4-fold above the estimated titre of maternal antibody
    • Geometric mean titres (GMTs) and median titers for poliovirus types 1, 2 and 3
    • Reverse cumulative titre distribution curves for poliovirus types 1, 2 and 3 at baseline and one month after 3rd vaccination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   54 Days to 75 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Infants 2 months of age (54-75 days of age) on date of first vaccination
  • Healthy assessed from medical history and physical examination
  • Parent(s)/guardian(s) have been properly informed about the trial and signed informed consent form
  • Parent(s)/guardian(s)granted access to the infant's trial related medical records
  • Parent(s)/guardian(s)are likely to comply with trial procedures

Exclusion Criteria:

  • Vaccinated with any polio vaccine other than the trial vaccines, prior to inclusion or planned during the trial
  • OPV vaccination or known exposure to poliovirus (wild or vaccine-derived) in household (living together) within 3 months prior to inclusion or planned during the trial
  • Low birth weight (< 2,500 g)
  • Known or suspected immunodeficiency (e.g. leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criteria
  • Severe uncontrolled chronic (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine) disease
  • Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)
  • Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling
  • Treatment with a product which is likely to modify the immune response (e.g. systemic corticosteroids, blood products and immunoglobulins) prior to inclusion or planned during the trial period
  • Participating in another clinical trial
  • Not suitable for inclusion in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03025750


Locations
Layout table for location information
Panama
Cevaxin
Panama City, Panama, 0816-00383
Sponsors and Collaborators
Statens Serum Institut
Bill and Melinda Gates Foundation
Larix A/S
Vaxtrials S.A.
AJ Vaccines
Investigators
Layout table for investigator information
Study Director: Ingrid Kromann Statens Serum Institut

Layout table for additonal information
Responsible Party: Statens Serum Institut
ClinicalTrials.gov Identifier: NCT03025750     History of Changes
Other Study ID Numbers: VIPV-07
First Posted: January 19, 2017    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Poliomyelitis
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Myelitis
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Spinal Cord Diseases
Neuromuscular Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs